Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Factor IXa crystals, related complexes and methods
8710188 Factor IXa crystals, related complexes and methods
Patent Drawings:

Inventor: Beyer, et al.
Date Issued: April 29, 2014
Application:
Filed:
Inventors:
Assignee:
Primary Examiner: Noakes; Suzanne M
Assistant Examiner:
Attorney Or Agent:
U.S. Class: 530/384; 436/4
Field Of Search:
International Class: A61K 35/14; C07K 1/00; C07K 17/00; G01N 31/00; A61K 38/48; C07K 14/00
U.S Patent Documents:
Foreign Patent Documents:
Other References: McKean, M.L. & Adelman, S.J., Expert Opin Investig Drugs 7:687-690 (1998). cited by applicant.
Weitz J.I. & Bates S.M.J. Thromb. Haemost. 3:1843-1853 (2005). cited by applicant.
Weber, Advances in Protein Chemistry 41:1-36 (1991). cited by applicant.
Giege, et al., Acta Crystallogr. D50: 339-350 (1994). cited by applicant.
McPherson, Eur. J. Biochem. 189: 1-23 (1990). cited by applicant.
McPherson, J. Biol. Chem. 251: 6300-6303 (1976). cited by applicant.
Schmidt et al., Trends Cardiovasc Med 13(1):39-45 (2003). cited by applicant.
Perera et al., Thromb Haemost 85:596-603 (2001). cited by applicant.
Howard et al., Arterioscler Thromb Vasc Biol 27:722-727 (2007). cited by applicant.
Lattman, Meth. Enzymol., 115: 55-77 (1985). cited by applicant.
Bricogne, G.,"The Bayesian Statistical Viewpoint on Structure Determination: Basic Concepts and Examples", in Methods in Enzymology, 276A, 361-423, C.W. Carter & R.M. Sweet, Eds. (1997). cited by applicant.
Roversi et al., "Modelling prior distributions of atoms for Macromolecular Refinement and Completion", Acta Cryst., D56, 1313-1323 (2000). cited by applicant.
Hopfner et al., EMBO, 16, 6626-6635 (1997). cited by applicant.









Abstract: The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.
Claim: We claim:

1. A method for determining the structure of a complex comprising a compound and a peptide bound to factor IXa protein, wherein said factor IXa is selected from the group consistingof SEQ ID NO: 14 and 18, said peptide comprises SEQ ID NO: 13 and said compound is selected from the group consisting of: ##STR00022## said method comprising: (a) mixing the factor IXa protein with the compound; (b) crystallizing said factor IXaprotein-compound complex; and (c) determining the three-dimensional structure of the complex which results in atomic coordinate data of any one of Tables 2-6 optionally varied by a root mean square deviation of conserved residue backbone atoms or ofalpha carbon atoms of less than about 1.5 .ANG. when superimposed on backbone atoms described in Table 2, 3, 4, 5 or 6, and wherein the resultant crystal of part (b) forms in one of in the following crystalline space groups and unit cell parameters: (i)space group P2.sub.12.sub.12.sub.1 having unit cell dimensions a=48.1 .ANG., b=69.8 .ANG., c=92.1 .ANG. and .alpha.=.beta.=.gamma.=90.degree. or space group P4.sub.32.sub.12 having unit cell dimensions a=100.4 .ANG., b=100.4 .ANG., c=97.3 .ANG. and.alpha.=.beta.=.gamma.=90.degree.; (ii) space group P4.sub.32.sub.12 having unit cell dimensions a=100.6 .ANG., b=100.6 .ANG., c=98.1 .ANG. and .alpha.=.beta.=.gamma.=90.degree.; (iii) space group P4.sub.32.sub.12 having unit cell dimensions a=99.2.ANG., b=99.2 .ANG., c=97.3 .ANG. and .alpha.=.beta.=.gamma.=90.degree.; and (iv) space group P4.sub.32.sub.12 having unit cell dimensions a=100.5 .ANG., b=100.5 .ANG., c=98.4 .ANG. and .alpha.=.beta.=.gamma.=90.degree..

2. A method for determining the structure of a complex comprising a first compound and a peptide bound to factor IXa protein and a second compound, wherein said factor IXa is selected from the group consisting of SEQ ID NO: 14 and 18, saidpeptide comprises SEQ ID NO: 13 and said first compound is selected from the group consisting of: ##STR00023## and wherein said second compound bound to said factor IXa protein is complexed with said first compound, said method comprising; (a) providinga crystal of factor IXa protein complexed with the first compound and the peptide, wherein said crystal forms in one of in the following crystalline space groups and unit cell parameters: (i) space group P2.sub.12.sub.12.sub.1 having unit cell dimensionsa=48.1 .ANG., b=69.8 .ANG., c=92.1 .ANG. and .alpha.=.beta.=.gamma.=90.degree. or space group P4.sub.32.sub.12 having unit cell dimensions a=100.4 .ANG., b=100.4 .ANG., c=97.3 .ANG. and .alpha.=.beta.=.gamma.=90.degree.; (ii) space groupP4.sub.32.sub.12 having unit cell dimensions a=100.6 .ANG., b=100.6 .ANG., c=98.1 .ANG. and .alpha.=.beta.=.gamma.=90.degree.; (iii) space group P4.sub.32.sub.12 having unit cell dimensions a=99.2 .ANG., b=99.2 .ANG., c=97.3 .ANG. and.alpha.=.beta.=.gamma.=90.degree.; and (iv) space group P4.sub.32.sub.12 having unit cell dimensions a=100.5 .ANG., b=100.5 .ANG., c=98.4 .ANG. and .alpha.=.beta.=.gamma.=90.degree.; (b) soaking the crystal with a second compound to form a complexbetween said factor IXa protein and said second compound; and (c) determining the structure of the complex to determine the three-dimensional structure which results in atomic coordinate which varies by a root mean square deviation of conserved residuebackbone atoms or of alpha carbon atoms of less than about 1.5 .ANG. when superimposed on backbone atoms described in Table 2, 3, 4, 5 or 6.

3. A method for identifying a substance which inhibits blood clotting or binds to factor IXa comprising (a) providing a crystal of factor IXa protein complexed with a first compound and a peptide, wherein said factor IXa is selected from thegroup consisting of SEQ ID NO: 14 and 18, said peptide comprises SEQ ID NO: 13 and said first compound is selected from the group consisting of: ##STR00024## and said crystal forms in one of in the following crystalline space groups and unit cellparameters: (i) space group P2.sub.12.sub.12.sub.1 having unit cell dimensions a=48.1 .ANG., b=69.8 .ANG., c=92.1 .ANG. and .alpha.=.beta.=.gamma.=90.degree. or space group P4.sub.32.sub.12 having unit cell dimensions a=100.4 .ANG., b=100.4 .ANG.,c=97.3 .ANG. and .alpha.=.beta.=.gamma.=90.degree.; (ii) space group P4.sub.32.sub.12 having unit cell dimensions a=100.6 .ANG., b=100.6 .ANG., c=98.1 .ANG. and .alpha.=.beta.=.gamma.=90.degree.; (iii) space group P4.sub.32.sub.12 having unit celldimensions a=99.2 .ANG., b=99.2 .ANG., c=97.3 .ANG. and .alpha.=.beta.=.gamma.=90.degree.; and (iv) space group P4.sub.32.sub.12 having unit cell dimensions a=100.5 .ANG., b=100.5 .ANG., c=98.4 .ANG. and .alpha.=.beta.=.gamma.=90.degree.; (b) soakingthe crystal comprising the first compound with a second substance to form a complex between said factor IXa protein and said second substance; and ((c) determining the structure of the complex to determine the three-dimensional structure which resultsin atomic coordinate which varies by a root mean square deviation of conserved residue backbone atoms or of alpha carbon atoms of less than about 1.5 .ANG. when superimposed on backbone atoms described in Table 2, 3, 4, 5 or 6; and, wherein if secondsaid substance is observed to complex with factor IXa, optionally determining if the second substance selectively inhibits factor IXa proteolytic activity but not factor Xa proteolytic activity; wherein the second substance is identified as a blotclotting inhibitor or factor IXa binder if said complex and/or selective inhibition is observed.

4. The method of claim 3 wherein said proteolytic activity is determined by measuring proteolysis of Methylsulfonyl-D-cyclohexylglycyl-glycyl-arginine-paranitroanilide.

5. A method for identifying a substance which binds to factor IXa or inhibits blood clotting comprising: (a) employing on a computer the structural coordinates of a complex comprising: a compound selected from the group consisting of I-IV, apeptide (SEQ ID NO: 13) and factor IXa (SEQ ID NO: 14 or 18) as set forth in any of Tables 2-6 and having a root-mean square deviation of less than 1.5 .ANG. from the backbone atoms or alpha carbon atoms thereof, to generate three-dimensional modelsthereof in silico; (b) utilizing the model(s) as generated in step (a) to analyze the interaction(s) of a candidate substance with the serine protease domain of factor IXa by computational docking means to determine the potential binding of saidsubstance to factor IXa; and (c) optionally, synthesizing said candidate substance and/or determining if said candidate substance binds to factor IXa or inhibits factor IXa proteolytic activity in vitro; And wherein compounds I-IV are: ##STR00025##
Description:
 
 
  Recently Added Patents
Method for producing (meth)acrylic anhydride, method for storing (meth)acrylic anhydride, and method for producing (meth)acrylate
Out-of-order load/store queue structure
Manufacturing process for cellular screening substratum, resultant substratum, and method and apparatus for screening
Parallel active optical cable
Rapid glycopeptide optimization via neoglycosylation
Compounds, compositions and methods for reducing lipid levels
MEMS structure and method for making the same
  Randomly Featured Patents
Injection molding system for threaded tamper indicating closures
Stencils having enhanced wear-resistance and methods of manufacturing the same
Disposal of waste aqueous boron trifluoride solutions
Optical connector, and method of assembling optical connector
Connecting element
System stabilization device
Wiring substrate and semiconductor device
Colored device for data display
Printing unit with anilox roller bearer positioning
Tension mask frame assembly for color CRT